The disease progression in prion diseases is probably due to the conformational change of the prion protein (PrP). PrP changes from alpha-helical conformation to a disease-associated, mainly beta-sheeted scrapie isoform (PrPSc), which forms amyloid aggregates. The drugs that contain N′-benzylidene-benzohydrazide core structure are likely to slow down this progression. Drugs that target PrPC, the normal prion isoform, are also hypothesized to delay the progression of prion diseases.
Antiprion drug
Antiviral drug
Chiral drugs
Antimanic drugs
Psychoactive drug
Cholinergic blocking drugs
Antihypertensive drug
Heroic medicine